-$0.29 Earnings Per Share Expected for Adverum Biotechnologies (ADVM) This Quarter

Equities analysts expect Adverum Biotechnologies (NASDAQ:ADVM) to post earnings of ($0.29) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Adverum Biotechnologies’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.27). Adverum Biotechnologies reported earnings of ($0.38) per share during the same quarter last year, which would indicate a positive year over year growth rate of 23.7%. The firm is expected to report its next earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that Adverum Biotechnologies will report full-year earnings of ($1.31) per share for the current financial year, with EPS estimates ranging from ($1.53) to ($1.13). For the next year, analysts expect that the firm will post earnings of ($1.35) per share, with EPS estimates ranging from ($1.51) to ($1.20). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Adverum Biotechnologies.

Adverum Biotechnologies (NASDAQ:ADVM) last issued its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.03. The company had revenue of $0.46 million for the quarter. Adverum Biotechnologies had a negative net margin of 3,036.61% and a negative return on equity of 29.61%.

Several equities research analysts have weighed in on ADVM shares. Piper Jaffray started coverage on shares of Adverum Biotechnologies in a research note on Thursday, February 15th. They issued an “overweight” rating and a $12.00 target price for the company. Zacks Investment Research upgraded shares of Adverum Biotechnologies from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Friday, March 23rd. ValuEngine upgraded shares of Adverum Biotechnologies from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 25th. Finally, BidaskClub downgraded shares of Adverum Biotechnologies from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $7.19.

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in Adverum Biotechnologies in the third quarter valued at approximately $108,000. BlueCrest Capital Management Ltd acquired a new stake in shares of Adverum Biotechnologies during the fourth quarter worth $111,000. Citadel Advisors LLC lifted its stake in shares of Adverum Biotechnologies by 365.1% during the fourth quarter. Citadel Advisors LLC now owns 47,189 shares of the biotechnology company’s stock worth $165,000 after buying an additional 37,042 shares during the period. Raymond James & Associates acquired a new stake in shares of Adverum Biotechnologies during the fourth quarter worth $172,000. Finally, Spark Investment Management LLC lifted its stake in shares of Adverum Biotechnologies by 64.2% during the fourth quarter. Spark Investment Management LLC now owns 66,821 shares of the biotechnology company’s stock worth $233,000 after buying an additional 26,121 shares during the period. Institutional investors own 36.69% of the company’s stock.

ADVM traded down $0.15 during trading on Friday, hitting $6.30. The stock had a trading volume of 316,025 shares, compared to its average volume of 579,416. The company has a market cap of $330.16, a price-to-earnings ratio of -4.88 and a beta of 3.65. Adverum Biotechnologies has a twelve month low of $2.40 and a twelve month high of $8.59.

WARNING: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3380413/0-29-earnings-per-share-expected-for-adverum-biotechnologies-advm-this-quarter.html.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, discovers and develops novel medicines for patients suffering from rare and ocular diseases. The company's pipeline includes product candidates, which are used for the treatment of wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema.

Get a free copy of the Zacks research report on Adverum Biotechnologies (ADVM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

TopBuild  Hits New 52-Week High and Low at $84.52
TopBuild Hits New 52-Week High and Low at $84.52
Nu Skin Enterprises  Sets New 52-Week High and Low at $81.72
Nu Skin Enterprises Sets New 52-Week High and Low at $81.72
Jaguar Health  Shares Gap Down to $0.14
Jaguar Health Shares Gap Down to $0.14
ValuEngine Downgrades LG Display  to Strong Sell
ValuEngine Downgrades LG Display to Strong Sell
GTX  Upgraded at ValuEngine
GTX Upgraded at ValuEngine
Community Health Systems  Upgraded at ValuEngine
Community Health Systems Upgraded at ValuEngine


© 2006-2018 Ticker Report. Google+.